@article{7a1d28cf0fbb46c9863e77ad3a2ee7b8,
title = "Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication",
abstract = "Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections.",
keywords = "2-Pyridinylmethylsulfinylbenzimidazoles, Anti-Bacterial Agents, Aza Compounds, Clarithromycin, Drug Combinations, Fluoroquinolones, Helicobacter Infections, Helicobacter pylori, Omeprazole, Patient Compliance, Quinolines, Treatment Outcome, 2-Pyridinylmethylsulfinylbenzimidazoles, Anti-Bacterial Agents, Aza Compounds, Clarithromycin, Drug Combinations, Fluoroquinolones, Helicobacter Infections, Helicobacter pylori, Omeprazole, Patient Compliance, Quinolines, Treatment Outcome",
author = "{Di Caro}, Simona and Veronica Ojetti and Zocco, {Maria Assunta} and Filippo Cremonini and F Bartolozzi and Marcello Candelli and Andrea Lupascu and Ec Nista and Giovanni Cammarota and Antonio Gasbarrini",
year = "2002",
language = "English",
volume = "16",
pages = "527--532",
journal = "ALIMENTARY PHARMACOLOGY & THERAPEUTICS",
issn = "0269-2813",
publisher = "Blackwell Science Limited:PO Box 88, Oxford OX2 0NE United Kingdom:011 44 1865 776868, 011 44 1865 206038, EMAIL:
[email protected], INTERNET: http://www.blackwell-science.com, Fax: 011 44 1865 721205",
}